Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“Breast Cancer Weekly Highlights | April 19–26, 2026
My take from this week’s publications in breast cancer
1. Association Between Tumor Size and Nodal Positivity for HER2+ and Triple-Negative Early-Stage Breast Cancer
Journal: Annals of Surgical Oncology
T1c HER2+ and TNBC tumors have substantial occult nodal risk, supporting careful preoperative axillary assessment and consideration of neoadjuvant therapy.
2. Comparison of T-DXd-Associated Pulmonary Toxicity in Real-World Settings and Clinical Trials
Journal: npj Breast Cancer
Real-world ILD severity with T-DXd may be higher than in phase III trials, reinforcing the need for structured monitoring and early recognition.
3. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial
Journal: Journal of Clinical Oncology
Long-term follow-up supports durable survival benefit with neoadjuvant durvalumab in early TNBC, even without adjuvant immunotherapy continuation.
4. Including Tumor-Infiltrating Lymphocytes into the PREDICT Prognostic Model for Triple-Negative Breast Cancer Survival
Journal: Annals of Oncology
Adding sTILs to PREDICT improves risk stratification in early TNBC and may help identify patients suitable for future de-escalation strategies.
5. Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial
Journal: CCR
Lobular breast cancer has distinct transcriptomic biology that may explain late relapse, endocrine sensitivity, and the need for ILC-specific risk refinement.
6. Identification of Cycling Regulatory T Cell Precursors as Conductors of Immune Escape During Breast Carcinoma Progression
Journal: Cancer Cell
Immune escape may begin early during DCIS-to-invasive progression, with cycling Tregs emerging as potential biomarkers and therapeutic targets.
7. Stage I TNBC: Moving From One-Size-Fits-All to a Personalized Approach
Journal: ASCO Educational Book
Stage I TNBC should not be managed as a single entity; tumor size, TILs, and emerging biomarkers may help balance overtreatment and recurrence risk.
8. The Evolving Landscape of CDK Inhibitor Use in BC Therapy and Beyond
Journal: Nature Reviews Drug Discovery
The next decade of CDK inhibition will require better biomarkers, rational sequencing, and next-generation inhibitors to overcome resistance.
9. Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
Journal: Annals of Oncology
For ADCs, “more stable” does not necessarily mean “better”; clinical performance depends on the full ADC system, not linker stability alone.
10. How I Read a Clinical Trial Report? A Primer for Busy Clinicians
Journal: JCO Oncology Practice
Before asking whether a trial is statistically positive, we should ask whether it is clinically meaningful, generalizable, ethically controlled, and relevant to the patient in front of us.”
Other Articles Featuring Benjamin Walbaum on OncoDaily.